Clinical Trial Update: Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing safety and efficacy of adding GSK2190915 to low-dose inhaled corticosteroid therapy in asthma patients aged 12 years and older.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK2190915

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-03